NanoViricides, Inc. (OTC BB: NNVC) (the "Company") recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide?, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.

The Company believes that the anti-HIV nanoviricide acts by a different mechanism than all the current components of HAART therapy regimens. We believe that the nanoviricide binds to a virus particle by mimicking the cellular structures to which the virus binds, as explained in the July 27 press release. As such, the Company anticipates that HIVCide would be able to complement almost any of the various HAART therapy regimens and provide additional therapeutic benefits. The Company believes that such a combination therapy that includes HIVCide would possibly achieve a "functional cure" of HIV/AIDS.

A functional cure is the highly sought after goal of HIV/AIDS therapy at present. After such a treatment protocol, the patient would be able to stop the treatment and lead a normal life, until a recurrence occurs by reactivation of HIV from the "sleeping" reservoir cells that contain HIV retroviral DNA. Upon such recurrence, the same therapy or a modified regimen could bring about a new disease-free period for the patient. This is somewhat akin to what happens with herpesviral infections at present. While current HSV therapies do not eliminate the herpesvirus completely, they provide disease-free periods until next recurrence.

The Company believes that it can rapidly improve its lead HIVCide candidate further, using its proven lead optimization technology. If such improvements can be made, the Company believes that the resulting drug therapy would provide substantial additional benefits.

"An example of the success of our 'lead optimization technology' was the dramatic improvement noted in results obtained with FluCide? for influenza. Over only a few cycles of optimization the Company has substantially improved effectiveness of its anti-influenza drug candidates," said Eugene Seymour, MD, MPH, the CEO of NanoViricides, adding, "We now intend to apply the same optimization techniques to our lead anti-HIV candidate."

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide? class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com